
Opinion|Videos|July 4, 2024
Tailoring CDK4/6 Inhibitor Treatment to Patient Needs
A leading breast cancer specialist examines the growing role of CDK4/6 inhibitors in the adjuvant treatment of HR+/HER2- early breast cancer, citing the monarchE and NATALEE trials, and explores patient and disease-related factors that guide the decision to incorporate CDK4/6 inhibitors in this context.
Advertisement
Episodes in this series

- In the adjuvant treatment of HR+/HER2- early breast cancer, endocrine therapy has traditionally played a crucial role, with CDK4/6 inhibitors becoming more prominent in recent years through the monarchE and NATALEE trials. What factors related to the patient or disease influences the decision to utilize a CDK4/6 inhibitor in this setting?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
USDA and HHS Update Dietary Guidelines to Encourage Real Food, Less Sugar
2
CDC Vaccine Rollback Highlights Gaps in Public Understanding of Shared Decision-Making
3
HERIZON-GEA-01 Results Indicate Potential 1L Use of Zanidatamab for Gastroesophageal Adenocarcinoma
4
β-Blockers Show No Added Benefit After MI With Preserved LVEF
5





























































